Palladia® Treatment of Dogs with Hypertension
Efficacy of toceranib phosphate (Palladia®) in dogs with spontaneously-arising pulmonary arterial hypertension: a proof-of-concept clinical trial.
Purpose and Brief Study Description:
Pulmonary arterial hypertension is a devastating disease for both dogs and humans, which is extremely difficult to treat effectively. Sildenafil (Viagra) is currently the drug of choice for treating dogs with pulmonary arterial hypertension, but the disease often becomes refractory to this therapy over time and no other effective agents are currently available. Toceranib phosphate (Palladia®) has been recently proposed as an alternative or complementary agent for the treatment of pulmonary arterial hypertension in dogs, given the efficacy of a related drug, imatinib, in humans, as well as anecdotal case reports in dogs. The primary purpose of this study, therefore, is to preliminarily evaluate the therapeutic efficacy and tolerability of toceranib phosphate (Palladia®) in dogs with spontaneously-arising pulmonary arterial hypertension.
Dogs that have been echocardiographically diagnosed with moderate to severe pulmonary arterial hypertension are eligible for this study. Dogs must have had a complete diagnostic work-up of their cardiac disease status at the VHC prior to study enrollment.
What does enrollment into this trial involve?
All dogs will receive toceranib phosphate (Palladia®) administered by mouth, by the owner, every other day for the duration of the study, which may be up to 6 months. Repeated echocardiograms will be performed monthly in order to monitor response to therapy. Blood and urine samples will be collected monthly in order to monitor for any systemic side-effects of the medication. After study day 168 (or sooner if your dog is removed from this study for any reason, such as progressive disease or medication side-effects), the study will be completed and the cardiology clinician will discuss additional and/or ongoing treatment options with you as the dog’s owner and primary caregiver.
Clients participating in this study will be granted special financial considerations. Specifically, the cost of Palladia® will be covered by the study for a duration of 6 months. Also covered by the study will be the required recheck appointments, monitoring blood tests, monitoring urine tests, monitoring blood pressure evaluations and any imaging studies deemed necessary by the clinician. Treatment required for any unanticipated side-effects will also be covered by the study up to $100 total per dog.
The owner is responsible for the costs of the initial appointment and the diagnostic work-up required prior to enrollment in the study to ensure your dog is an appropriate study candidate. This may include the initial echocardiogram, blood tests, urinalysis, blood pressure measurement and any additional imaging studies.